{"organizations": [], "uuid": "b6845a40163ef071fc5e584dc82944d0a1ec3257", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-bristol-myers-squibb-receives-posi/brief-bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-opdivo-four-week-dosing-schedule-for-advanced-melanoma-and-previously-treated-renal-cell-carcinoma-idUSFWN1R80DM", "country": "US", "domain_rank": 408, "title": "BRIEF-Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo Four-Week Dosing Schedule For Advanced Melanoma And Previously Treated Renal Cell Carcinoma", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-26T14:05:00.000+03:00", "replies_count": 0, "uuid": "b6845a40163ef071fc5e584dc82944d0a1ec3257"}, "author": "", "url": "https://www.reuters.com/article/brief-bristol-myers-squibb-receives-posi/brief-bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-opdivo-four-week-dosing-schedule-for-advanced-melanoma-and-previously-treated-renal-cell-carcinoma-idUSFWN1R80DM", "ord_in_thread": 0, "title": "BRIEF-Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo Four-Week Dosing Schedule For Advanced Melanoma And Previously Treated Renal Cell Carcinoma", "locations": [], "entities": {"persons": [], "locations": [{"name": "eu", "sentiment": "none"}], "organizations": [{"name": "reuters) - bristol-myers squibb co", "sentiment": "none"}, {"name": "advanced melanoma and previously treated renal cell carcinoma reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " Bristol-Myers Squibb Co:\n* BRISTOL-MYERS SQUIBB RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF OPDIVO FOUR-WEEK DOSING SCHEDULE FOR ADVANCED MELANOMA AND PREVIOUSLY TREATED RENAL CELL CARCINOMA\n* BRISTOL-MYERS SQUIBB CO - ‍CHMP RECOMMENDATION OF OPDIVO WILL NOW BE REVIEWED BY EUROPEAN COMMISSION​\n* BRISTOL-MYERS - CHMP ALSO RECOMMENDED APPROVAL OF TWO-WEEK OPDIVO DOSING OPTION OF 240 MG TO REPLACE WEIGHT-BASED DOSING FOR APPROVED MONOTHERAPIES IN EU\n* BRISTOL-MYERS SQUIBB CO - CHMP RECOMMENDATION WILL NOW BE REVIEWED BY EUROPEAN COMMISSION Source text for Eikon: ", "external_links": [], "published": "2018-03-26T14:05:00.000+03:00", "crawled": "2018-03-26T14:24:43.013+03:00", "highlightTitle": ""}